Core Viewpoint - WuXi AppTec, a leading CRO company, has completed a share repurchase of approximately 1 billion yuan, marking its second repurchase in 2025, with a total of 40 billion yuan repurchased since 2024 [1][2][3] Group 1: Share Repurchase - The company has completed its second share repurchase in 2025, buying back 15.7754 million shares at an average price of 63.39 yuan per share, totaling around 1 billion yuan [2] - Since 2024, WuXi AppTec has conducted five "cancellation-style" repurchases, with four completed, amounting to a total of 40 billion yuan [1][3] - The purpose of these repurchases is to reduce the company's registered capital and enhance shareholder value [2][3] Group 2: Financial Performance - Since its IPO in 2018, WuXi AppTec has achieved a cumulative net profit of 43.716 billion yuan and a total cash dividend of 13.93 billion yuan, with a dividend payout ratio of 31.87% [1][3] - In Q1 2025, the company reported a revenue of 9.65 billion yuan, a year-on-year increase of approximately 21%, and a net profit of 3.673 billion yuan, reflecting a growth of 89.06% [4][5] - The company’s order backlog as of March 2025 stands at 52.33 billion yuan, a year-on-year increase of 47.1% [6]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-042 无锡药明康德新药开发股份有限公司 关于 2025 年第一次以集中竞价交易方式回购 A 股股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：无锡药明康德新药开发股份有限公司（以下简称"公司"） 本次回购资金总额为人民币 10 亿元。 一、 回购方案的审议及实施程序 别股东会议和 2025 年第一次 H 股类别股东会议审议通过了《关于给予董事会回购 公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规 和/或规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过 该议案经股东大会、A 股及 H 股类别股东会议分别审议通过之日公司已发行 A 股 和/或 H 股股份数量的 10%（以下简称"A 股回购一般性授权"）。如果公司前述 A 股回购一般性授权的授权期限届满前未完成本次回购股份，在本次回购股份数量 上限不超过公司股东大会及类别股东会批准的下一年度 A 股 ...

Group 1 - The China Strategic Emerging Industries Index (new emerging index, 000171) rose by 1.66% to 1188.03 points, with a trading volume of 110.449 billion yuan [1] - Over the past month, the index increased by 1.27%, while it decreased by 3.76% over the past three months and has fallen by 1.33% year-to-date [1] - The index includes 100 representative listed companies from sectors such as energy conservation and environmental protection, new generation information technology, biotechnology, high-end equipment manufacturing, new energy, new materials, new energy vehicles, digital creativity, and high-tech services [1] Group 2 - The top ten holdings in the index are BYD (8.72%), Dongfang Wealth (8.59%), Hengrui Medicine (5.81%), Zhongji Xuchuang (3.47%), Xinyi Sheng (3.3%), Haiguang Information (3.18%), Luxshare Precision (3.15%), WuXi AppTec (3.13%), Huichuan Technology (3.01%), and Northern Huachuang (2.61%) [1] - The market capitalization distribution of the index shows that 61.12% of the holdings are listed on the Shenzhen Stock Exchange, while 38.88% are on the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index includes Information Technology (33.01%), Healthcare (15.20%), Communication Services (12.90%), Industry (12.37%), Consumer Discretionary (11.33%), Financials (9.11%), Materials (5.16%), Utilities (0.38%), Consumer Staples (0.31%), and Energy (0.24%) [2] - The index samples are adjusted biannually, with adjustments implemented on the next trading day after the second Friday of June and December [2] - Public funds tracking the new emerging index include Huaxia Strategic Emerging Index ETF Link A, Huaxia Strategic Emerging Index ETF Link C, and Huaxia Strategic Emerging Index ETF [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 无锡药明康德新药开发股份有限公司 董事長 李革博士 香港，2025年6月24日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-042 关于 2025 年第一次以集中竞价交易方式回购 A 股股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在 ...

关于 2025 年第一次以集中竞价交易方式回购 A 股股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：603259 证券简称：药明康德 公告编号：临 2025-042 无锡药明康德新药开发股份有限公司 ● 回购股份金额：无锡药明康德新药开发股份有限公司（以下简称"公司"） 本次回购资金总额为人民币 10 亿元。 ● 回购股份资金来源：公司自有资金和自筹资金。 ● 回购股份用途：本次回购的股份将用于注销并减少公司注册资本。 ● 回购股份价格：本次回购股份价格原为不超过人民币 92.05 元/股（含），即 不高于董事会通过本次回购股份方案的决议前 30 个交易日公司股票交易均价的 150%，因实施 2024 年度及 2025 年回报股东特别分红 A 股权益分派，前述回购股 份价格上限由不超过人民币 92.05 元/股（含）调整为不超过人民币 90.72 元/股（含）。 ● 回购股份方式：通过上海证券交易所系统以集中竞价交易方式回购 A 股股 票。 ● 回购股份期限：本次回购股份的期限 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月24日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年6月20日 | 2,500,916,432 | | 0 | | 2,500,916,432 | | 1). 購回股份 (股份購回並註銷) | | -15,775,377 | 0.63 % | RMB | 63.39 | | | 茲提述本公司於 ...

Group 1: Stock Resumption and Suspension - Huasheng Co. plans to acquire 100% of Yixin Technology, leading to stock resumption [1] - Tianyi Ma intends to purchase 100% equity of intelligent self-service equipment company Xingyun Kaiwu, resulting in stock resumption [1] - Guotou Zhonglu is set to acquire controlling interest in Electronic Institute, and will continue to suspend trading [1] - Zhongda An's controlling shareholder is planning to issue shares to specific targets, causing a change in control and continued suspension of trading [1] Group 2: Share Buybacks and Equity Transfers - Inspur Information plans to repurchase shares worth 200 million to 300 million yuan to reduce registered capital [2] - WuXi AppTec has completed a 1 billion yuan share buyback and plans to cancel the shares [2] - Shanghai Mechanical and Electrical's controlling shareholder intends to transfer 5% of shares through an agreement [2] - Cambrian has adjusted the upper limit for share repurchase price to no more than 818.87 yuan per share [2] Group 3: Daily Operations and External Investments - JinkoSolar has achieved a record conversion efficiency of 27.02% for its 182N-type high-efficiency monocrystalline silicon cells [3] - Wanyi Technology has established a joint laboratory for the development of key vacuum measurement equipment for nuclear fusion [3] - Hailianxun's application for a stock swap merger with Hangqilun has been accepted by the Shenzhen Stock Exchange [3] - Baotai has signed a licensing and production agreement with SteinCares for BAT2406 (Dupilumab) injection [3] - Tailinwei's sales of edge AI new products reached a scale of 10 million yuan in the second quarter [3] - Guiguan Electric is investing 9.5 billion yuan in the construction of a photovoltaic project [3] - Songsheng Co. has signed a contract with Chongqing Jingang Transmission for the development of robotic harmonic reducers and intelligent joint technology [3] - Huilv Ecology's silicon optical single-mode products have entered mass production [3] - Hongmian Co. plans to acquire 39.99% equity of Asia Foods for 90.28 million yuan and accept 60% voting rights delegation [3]

Core Viewpoint - WuXi AppTec (02359) announced a share buyback plan to enhance company value and protect shareholder interests, with a total fund of RMB 1 billion allocated for the buyback [1] Group 1: Buyback Plan Details - The second share buyback plan for 2025 was approved on April 8, 2025, allowing the company to repurchase A-shares at a maximum price of RMB 97.24 per share, later adjusted to RMB 95.91 due to profit distribution [1] - The buyback period is set for a maximum of three months from the board's approval date, with all repurchased shares to be canceled and registered capital reduced [1] Group 2: Execution of Buyback - As of June 20, 2025, the company completed the buyback, acquiring 15.7754 million A-shares, representing 0.5462% of the total issued share capital [2] - The highest buyback price was RMB 69.87 per share, the lowest was RMB 52.52, and the average price was RMB 63.39, with a total expenditure of RMB 10 million (excluding transaction fees) [2] - The execution of the buyback plan did not significantly impact the company's operations, finances, or future development, nor did it affect the company's compliance with listing conditions [2]

有關完成2025年第二次回購本公司A股及 註銷本公司A股的公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 茲提述無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年4月8日及2025 年5月14日的公告（「該等公告」），內容有關（其中包括）2025年第二次以集中競 價交易方式回購本公司A股股份方案（「2025年第二次股份回購方案」）及實施 2024年度利潤分配及2025年特別股息分派後調整A股回購價格上限。除非文義 另有所指，否則該等公告已界定的詞語在本公告中具有相同涵義。 為積極維護本公司價值及股東權益，本公司於2025年4月8日召開第三屆董事會 第二十次會議，審議並通過了《關於2025年第二次以集中競價交易方式回購公 司A股股份的議案》，同意使用自有資金和╱或自籌資金以集中競價交易方式 回 ...